A Phase 1 Study of JNJ-86974680, an A2a Receptor Antagonist, Administered as Monotherapy and in Combination With Cetrelimab and Radiotherapy for Advanced Non-Small Cell Lung Cancer

This study is testing a new drug, called JNJ-86974680, to see how it works alone or in combination with other treatments for advanced lung cancer. The main goal is to find a safe dose that might help fight the cancer more effectively.

This trial is for adults with advanced non-small cell lung cancer who have already tried other standard treatments like chemotherapy or immunotherapy. Depending on the specific type of lung cancer, participants may need to have certain genetic mutations or have previously tried targeted therapies.

Participants will receive the study drug, either alone or alongside an immunotherapy drug called cetrelimab and radiation therapy. Researchers will closely monitor your health to determine the safest dosage and watch how your body responds to the treatment.

The study is currently active but not looking for new patients at locations in Georgia, New Jersey, and New York. You can talk to your doctor to see if similar research opportunities might be available in the future.